Link to journal paper:
Paper · Aging Biol · 2024Ezetimibe Lowers Risk of Alzheimer's and Related Dementias over Sevenfold, Reducing Aggregation in Model Systems by Inhibiting 14-3-3G::Hexokinase Interaction.Numerous factors predispose to progression of cognitive impairment to Alzheimer's disease and related dementias (ADRD), most notably age, APOE(ε4) alleles, traumatic brain injury, heart disease, hypertension, obesity/diabetes, and Down's syndrome. Protein aggregation is diagnostic for neurodegenerative diseases, and may be causal through promotion of chronic neuroinflammation. We isolated aggregates from postmortem…pmc.ncbi.nlm.nih.govLink to accompanying editorial (by geroscientist Vera Gorbunova):
agingcelljournal.orgAging Biology | Hiding in Plain Sight: FDA-Approved Cholesterol Drug Ezetimibe as a Treatment for Alzheimer’sOur mission is to publish high quality research on the fundamental mechanisms of aging and longevity.agingcelljournal.org